George Farmer
Stock Analyst at Scotiabank
(2.11)
# 2,955
Out of 4,981 analysts
70
Total ratings
47.37%
Success rate
-5.77%
Average return
Main Sectors:
Top Industries:
Stocks Rated by George Farmer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMEA Biomea Fusion | Maintains: Sector Outperform | $30 → $10 | $1.96 | +410.20% | 4 | Aug 6, 2025 | |
| ACLX Arcellx | Maintains: Sector Outperform | $93 → $133 | $75.20 | +76.86% | 3 | Jul 31, 2025 | |
| INMB INmune Bio | Downgrades: Sector Underperform | $23 → $0.6 | $1.97 | -69.54% | 3 | Jul 1, 2025 | |
| URGN UroGen Pharma | Maintains: Sector Outperform | $23 → $47 | $18.06 | +160.24% | 1 | Jun 13, 2025 | |
| SNDX Syndax Pharmaceuticals | Maintains: Sector Perform | $16 → $17 | $15.84 | +7.32% | 4 | May 6, 2025 | |
| TARA Protara Therapeutics | Initiates: Sector Outperform | $12 | $3.16 | +279.75% | 1 | Apr 16, 2025 | |
| TPST Tempest Therapeutics | Downgrades: Sector Perform | $91 → $9 | $9.92 | -9.27% | 4 | Apr 10, 2025 | |
| ADAP Adaptimmune Therapeutics | Maintains: Sector Outperform | $3.15 → $1.4 | $0.07 | +2,002.10% | 2 | Mar 21, 2025 | |
| JANX Janux Therapeutics | Maintains: Sector Perform | $62 → $41 | $23.56 | +74.02% | 4 | Feb 28, 2025 | |
| NAMS NewAmsterdam Pharma Company | Maintains: Sector Outperform | $47 → $52 | $24.12 | +115.59% | 4 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $78 → $80 | $53.14 | +50.55% | 8 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $244 → $224 | $143.32 | +56.29% | 3 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $102 | $24.09 | +323.50% | 1 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $18 → $10 | $8.21 | +21.80% | 2 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Sector Outperform | $439 → $715 | $756.83 | -5.53% | 5 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $20 → $23 | $5.97 | +285.26% | 2 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $20 | $4.07 | +391.40% | 1 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $70 → $76 | $33.88 | +124.32% | 4 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $13 | $2.62 | +396.18% | 1 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $109 | $23.88 | +356.45% | 3 | Nov 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $94 → $87 | $83.14 | +4.64% | 5 | Nov 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $33 | $3.57 | +824.37% | 1 | Oct 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $0.77 | +5,073.31% | 1 | Jul 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $20 → $27 | $39.01 | -30.79% | 3 | May 6, 2020 |
Biomea Fusion
Aug 6, 2025
Maintains: Sector Outperform
Price Target: $30 → $10
Current: $1.96
Upside: +410.20%
Arcellx
Jul 31, 2025
Maintains: Sector Outperform
Price Target: $93 → $133
Current: $75.20
Upside: +76.86%
INmune Bio
Jul 1, 2025
Downgrades: Sector Underperform
Price Target: $23 → $0.6
Current: $1.97
Upside: -69.54%
UroGen Pharma
Jun 13, 2025
Maintains: Sector Outperform
Price Target: $23 → $47
Current: $18.06
Upside: +160.24%
Syndax Pharmaceuticals
May 6, 2025
Maintains: Sector Perform
Price Target: $16 → $17
Current: $15.84
Upside: +7.32%
Protara Therapeutics
Apr 16, 2025
Initiates: Sector Outperform
Price Target: $12
Current: $3.16
Upside: +279.75%
Tempest Therapeutics
Apr 10, 2025
Downgrades: Sector Perform
Price Target: $91 → $9
Current: $9.92
Upside: -9.27%
Adaptimmune Therapeutics
Mar 21, 2025
Maintains: Sector Outperform
Price Target: $3.15 → $1.4
Current: $0.07
Upside: +2,002.10%
Janux Therapeutics
Feb 28, 2025
Maintains: Sector Perform
Price Target: $62 → $41
Current: $23.56
Upside: +74.02%
NewAmsterdam Pharma Company
Feb 27, 2025
Maintains: Sector Outperform
Price Target: $47 → $52
Current: $24.12
Upside: +115.59%
Feb 20, 2025
Maintains: Sector Perform
Price Target: $78 → $80
Current: $53.14
Upside: +50.55%
Feb 13, 2025
Maintains: Sector Outperform
Price Target: $244 → $224
Current: $143.32
Upside: +56.29%
Feb 13, 2025
Initiates: Sector Outperform
Price Target: $102
Current: $24.09
Upside: +323.50%
Jan 8, 2025
Maintains: Sector Perform
Price Target: $18 → $10
Current: $8.21
Upside: +21.80%
Nov 5, 2024
Upgrades: Sector Outperform
Price Target: $439 → $715
Current: $756.83
Upside: -5.53%
Oct 18, 2024
Maintains: Sector Outperform
Price Target: $20 → $23
Current: $5.97
Upside: +285.26%
Sep 30, 2024
Initiates: Sector Outperform
Price Target: $20
Current: $4.07
Upside: +391.40%
Aug 12, 2024
Maintains: Sector Outperform
Price Target: $70 → $76
Current: $33.88
Upside: +124.32%
Mar 14, 2024
Initiates: Sector Outperform
Price Target: $13
Current: $2.62
Upside: +396.18%
Nov 17, 2020
Downgrades: Market Perform
Price Target: $109
Current: $23.88
Upside: +356.45%
Nov 6, 2020
Maintains: Market Perform
Price Target: $94 → $87
Current: $83.14
Upside: +4.64%
Oct 27, 2020
Initiates: Outperform
Price Target: $33
Current: $3.57
Upside: +824.37%
Jul 20, 2020
Initiates: Outperform
Price Target: $40
Current: $0.77
Upside: +5,073.31%
May 6, 2020
Maintains: Market Perform
Price Target: $20 → $27
Current: $39.01
Upside: -30.79%